For manufacturers without a UK presence, the UKRP is not optional. It is the regulatory backbone ensuring that devices are correctly registered, technically compliant, traceable, and monitored post-market.
And MHRA oversight is tightening. The latest UKRP guidance from 2024 confirms increased scrutiny on registrations, vigilance, and the separation of roles across importers, distributors, and UKRPs.
The message is clear: in 2025, the UKRP is no longer a “checkbox role.” It is a central compliance partner. Furthermore, appointing the wrong one can lead to deregistration, delayed market access, or an MHRA investigation.
Need a trusted UK Responsible Person? Patient Guard provides full UKRP representation and MHRA registration services.
What is a UK Responsible Person (UKRP)?
A UK Responsible Person for medical devices is a UK-established regulatory representative legally appointed by a non-UK manufacturer to act on their behalf.
The UKRP is required whenever:
- The manufacturer is not established in the UK.
- The device will be placed on the Great Britain market.
Manufacturers often assume a distributor or importer can fulfil the role, but under UK MDR, they cannot automatically act as a UKRP. A UKRP is an explicitly defined regulatory representative with its own set of duties, liabilities, and documentation responsibilities.
The legal basis – UK MDR 2002 (as Amended)
UKRP requirements are set out in the UK MDR 2002 legislation, which incorporates amendments reflecting the post-Brexit landscape. These rules govern classification, conformity assessment routes, device registration, PMS, vigilance, and manufacturer responsibilities.
Key legal points to consider:
- CE marking remains accepted until June 2030, after which UKCA becomes mandatory.
- UKRPs must be listed on MHRA’s DORS (Device Online Registration System).
- The UKRP must hold the manufacturer’s technical documentation and be able to provide it to MHRA within agreed timeframes.
Statistic #1: MHRA 2024 registration trends show continued year-on-year growth in UKRP appointments, driven by increased scrutiny of non-UK manufacturers and post-market records.
UK Responsible Person duties and responsibilities
Under UK MDR, the UKRP acts as the regulatory anchor between the manufacturer and the MHRA. Think of it as a compliance “hub,” ensuring continuity, communication, and documentation integrity.
Device registration (DORS)
The UKRP registers devices on behalf of the manufacturer in MHRA’s Device Online Registration System (DORS).
Key duties include:
- Complete initial device registrations.
- Maintain up-to-date details following product or certificate changes.
- Hold evidence of valid CE or UKCA conformity (during transition).
Declaration of Conformity & technical documentation
The UKRP must verify that:
- The manufacturer has completed a Declaration of Conformity.
- The full technical file and supporting documents are ready for inspection.
This includes:
- Risk management
- Clinical evaluation
- PMS and PMCF plans
- Design and manufacturing information
- Labelling and IFUs
The UKRP must have continuous access to these documents.
Communication with MHRA
The MHRA does not communicate directly with non-UK manufacturers for regulatory matters.
The UKRP is responsible for:
- Submitting vigilance reports
- Handling corrective actions (FSNs / FSCAs)
- Responding to MHRA information requests
- Managing communication for safety investigations
Post-Market Surveillance (PMS) & vigilance
The UKRP must:
- Maintain vigilance records
- Ensure incident reporting timelines are met
- Oversee field safety corrective actions
- Support PMS data collection
- Validate the PMS documentation provided by the manufacturer
Labelling and information verification
Manufacturers must list their UK Responsible Person’s details on packaging, IFU, or outer labelling. These details include:
- Full legal name
- UK address
- Contact details
Any mislabelling is treated as a regulatory violation.
Cooperation during inspections
The MHRA may request:
- Technical files
- PMS reports
- Incident logs
- Complaint handling records
The UKRP must provide these promptly and accurately.
How to appoint a UK Responsible Person
Appointing a UKRP is a structured legal process.
Eligibility criteria
A UKRP must:
- Be a UK-based legal entity
- Have regulatory competence
- Maintain access to the manufacturer’s technical documentation
- Agree to the legal liabilities of the role
- Not act simultaneously as an importer for the same device
This separation avoids conflicts of interest.
Appointment process
A typical UKRP appointment includes:
- Regulatory contract defining obligations and liabilities
- Written mandate from the manufacturer
- Submission of the manufacturer and device details to DORS
- Technical file transfer and review
- Confirmation of vigilance, PMS, and complaint handling responsibilities
- Ongoing updates for new devices, changes, or certificate renewals
Documents required
- Manufacturer declaration and mandate
- Device list with classifications
- CE/UKCA certificates or conformity assessment documents
- Technical file availability statement
- PMS and vigilance procedures
UKRP vs EU Authorised Representative
Although similar in purpose, the two roles differ across legal frameworks.
Requirement | UK Responsible Person | EU Authorised Representative |
Legal basis | UK MDR 2002 | EU MDR 2017/745 |
Jurisdiction | Great Britain | EU + Northern Ireland |
Regulatory authority | MHRA | EU Competent Authorities |
Device markings | CE (until 2030) or UKCA | CE |
Mandate | Written manufacturer mandate | Written manufacturer mandate |
Tech doc access | Required | Required |
Vigilance responsibility | Required | Required |
A manufacturer distributing to both regions will need both an EU Authorised Representative and a UK Responsible Person.
Related post: CE Marking and Supply Chain Responsibilities
Ongoing compliance obligations
UKRP responsibilities do not stop once a device is registered. The MHRA expects active involvement. Manufacturers often underestimate the ongoing workload required to stay compliant.
Manufacturer duties include:
- Updating registrations after design or supply-chain changes
- Maintaining vigilance and PMS documentation
- Managing incident reports
- Ensuring traceability
- Supporting audits and investigations
- Annual technical documentation reviews
Insight:
MHRA 2024 enforcement data shows increased vigilance investigations involving imported devices, prompting tighter oversight of UKRPs and distributors.
Common mistakes and how to avoid them
Typical pitfalls include:
- Appointing a distributor as UKRP without assessing competence
- Missing updates after device modifications
- Incomplete technical documentation
- Lack of communication between the manufacturer and UKRP
- No written mandate or unclear allocation of responsibilities
- Assuming EU MDR compliance alone is sufficient
Compliance health check:
- Is the UKRP contract up to date?
- Are all devices registered correctly in DORS?
- Are PMS + vigilance documents updated?
- Are the importer and UKRP roles clearly separated?
- Are label details accurate and visible?
Benefits of partnering with a professional UKRP
A professional UKRP goes beyond registration, offering end-to-end regulatory protection. Advantages of choosing an expert regulatory body like Patient Guard include:
- Seamless MHRA communication
- Precise DORS registrations
- Proactive vigilance and PMS monitoring
- Regulatory alignment with UK MDR and upcoming MHRA reforms
- High-quality documentation handling and retention
- Support for both UKCA and CE routes during transition
Choosing a specialist ensures consistency, speed, and credibility — all essential for market access.
CTA: Get expert representation today.— Appoint Patient Guard as your UK Responsible Person. Get in touch.
The future of UKRP requirements (2026 and beyond)
The MHRA’s regulatory reform programme continues to evolve. Updates from 2025 include:
- More substantial alignment with IMDRF frameworks
- Enhanced digital reporting systems
- Updated vigilance requirements
- Potential changes to PMS cycles
- Refined rules for software and AI devices
- Stricter oversight of economic operators (importers, distributors, UKRPs)
Manufacturers should review current UKRP agreements, PMS procedures, and DORS registrations to stay ahead of regulatory change.
Wrapping up
The UK Responsible Person is now an essential part of navigating the post-Brexit medical device landscape. Without a compliant UKRP, non-UK manufacturers cannot legally place devices on the Great Britain market — and MHRA enforcement is increasing.
Choosing a competent, proactive UKRP ensures:
- Reliable registration
- Strong PMS and vigilance oversight
- Consistent communication with MHRA
- Protection against regulatory findings
- Smooth UKCA transition ahead of 2030
Appoint Patient Guard as your trusted UK Responsible Person and stay fully compliant with UK MDR 2002 requirements. Speak to an expert today.
Frequently Asked Questions
A UKRP is a UK-based regulatory representative legally appointed by a non-UK manufacturer to manage registrations, documentation, PMS, and vigilance.
Any medical device manufacturer without a UK establishment must appoint a UKRP before placing devices on the GB market.
They operate in different jurisdictions (UK vs EU) and under other legislation (UK MDR vs EU MDR).
Registration, PMS/vigilance, label verification, MHRA communication, and access to technical documentation.
Not automatically. They must meet full UKRP criteria and accept legal liability.
Through UKRP representation, MHRA registration, PMS, vigilance, documentation support, and upcoming regulatory reform guidance.
Patient Guards Recent Posts
CE Marking vs UKCA: 2026 Guide for Manufacturers
Post-Brexit, many medical device manufacturers are still navigating the split between CE marking and the UKCA mark — and the rules keep evolving. As the MHRA advances its “future regime” for medical devices, regulatory teams face the ongoing challenge of complying with both EU MDR obligations and the UK’s own UK MDR 2002 (as amended) framework.
ISO 10993-1:2025 – What’s New in Biological Evaluation
The newly revised ISO 10993-1:2025 has quietly done something big: it’s turned biological evaluation from a “tick-the-box biocompatibility test list” into a fully integrated risk narrative that regulators now expect to hold together scientifically, from chemistry through to clinical data.
EUDAMED Mandatory from May 2026: What You Need to Know
After years of “coming soon”, the EU has finally put a fixed date on reality: the first EUDAMED mandatory modules must be used from 28 May 2026.
